A Phase 2, Open-label Study to Explore the Pharmacodynamic and Clinical Effects of Mongersen (GED-0301) in Subjects With Active Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Mongersen (Primary)
- Indications Crohn's disease
- Focus Pharmacodynamics
- Sponsors Celgene Corporation
- 28 Jun 2017 Phase has been changed from Phase 3 to Phase 2.
- 28 Jun 2017 Planned End Date changed from 28 Feb 2019 to 25 Jul 2019.
- 28 Jun 2017 Planned primary completion date changed from 30 May 2017 to 30 May 2019.